In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Apr 8

PMID 35392094

Authors

Carole Chedid

Thibault Andrieu

Eka Kokhreidze

Nestani Tukvadze

Samanta Biswas

Md Fahim Ather

Mohammad Khaja Mafij Uddin

Sayera Banu

Flavio De Maio

Giovanni Delogu

Hubert Endtz

Delia Goletti

Marc Vocanson

Oana Dumitrescu

Jonathan Hoffmann

Florence Ader

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is a difficult-to-treat infection because of multidrug regimen requirements based on drug susceptibility profiles and treatment observance issues. TB cure is defined by mycobacterial sterilization, technically complex to systematically assess. We hypothesized that microbiological outcome was associated with stage-specific immune changes in peripheral whole blood during TB treatment. The T-cell phenotypes of treated TB patients were prospectively characterized in a blinded fashion using mass cytometry after () antigen stimulation with QuantiFERON-TB Gold Plus, and then correlated to sputum culture status. At two months of treatment, cytotoxic and terminally differentiated CD8 T-cells were under-represented and naïve CD4 T-cells were over-represented in positive- negative-sputum culture patients, regardless of drug susceptibility. At treatment completion, a T-cell immune shift towards differentiated subpopulations was associated with TB cure. Overall, we identified specific T-cell profiles associated with slow sputum converters, which brings new insights in TB prognostic biomarker research designed for clinical application.

Citing Articles

Immunophenotyping of T Cells in Lung Malignancies and Cryptogenic Organizing Pneumonia.

Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K J Clin Med. 2025; 14(2.

PMID: 39860323 PMC: 11766438. DOI: 10.3390/jcm14020316.

Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.

Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K Elife. 2024; 12.

PMID: 38607373 PMC: 11014725. DOI: 10.7554/eLife.87288.

Comparison of the Single Cell Immune Landscape between Subjects with High Bacillary Loads during Active Pulmonary Tuberculosis and Household Members with Latent Tuberculosis Infection.

Kamolratanakul S, Ariyanon W, Udompornpitak K, Bhunyakarnjanarat T, Leelahavanichkul A, Dhitavat J Cells. 2024; 13(4.

PMID: 38391975 PMC: 10887672. DOI: 10.3390/cells13040362.

New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review.

Zhang F, Zhang F, Dong Y, Li L, Pang Y Infect Dis Ther. 2023; 12(12):2665-2689.

PMID: 37938418 PMC: 10746651. DOI: 10.1007/s40121-023-00887-x.

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment.

Ndiaye M, Ranaivomanana P, Rasoloharimanana L, Rasolofo V, Ratovoson R, Herindrainy P Sci Rep. 2022; 12(1):20640.

PMID: 36450921 PMC: 9712643. DOI: 10.1038/s41598-022-25236-9.

References

Scriba T, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi S, Borate B . Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021; 21(3):354-365. PMC: 7907670. DOI: 10.1016/S1473-3099(20)30914-2. View

Agrawal S, Parkash O, Palaniappan A, Bhatia A, Kumar S, Chauhan D . Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response. Front Immunol. 2018; 9:157. PMC: 5810270. DOI: 10.3389/fimmu.2018.00157. View

Adekambi T, Ibegbu C, Cagle S, Kalokhe A, Wang Y, Hu Y . Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest. 2015; 125(5):1827-38. PMC: 4598074. DOI: 10.1172/JCI77990. View

Kourelis T, Villasboas J, Jessen E, Dasari S, Dispenzieri A, Jevremovic D . Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer J. 2019; 9(9):72. PMC: 6713712. DOI: 10.1038/s41408-019-0234-4. View

Moguche A, Musvosvi M, Penn-Nicholson A, Plumlee C, Mearns H, Geldenhuys H . Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe. 2017; 21(6):695-706.e5. PMC: 5533182. DOI: 10.1016/j.chom.2017.05.012. View

Genestet C, Hodille E, Barbry A, Berland J, Hoffmann J, Westeel E . Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion. PLoS Pathog. 2021; 17(6):e1009643. PMC: 8224949. DOI: 10.1371/journal.ppat.1009643. View

Mei H, Leipold M, Schulz A, Chester C, Maecker H . Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry. J Immunol. 2015; 194(4):2022-31. PMC: 4323739. DOI: 10.4049/jimmunol.1402661. View

Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S, Jaxa L . T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.00153-2018. View

Althouse A . Adjust for Multiple Comparisons? It's Not That Simple. Ann Thorac Surg. 2016; 101(5):1644-5. DOI: 10.1016/j.athoracsur.2015.11.024. View

10.

Chedid C, Kokhreidze E, Tukvadze N, Banu S, Khaja Mafij Uddin M, Biswas S . Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. Int J Infect Dis. 2020; 100:199-206. DOI: 10.1016/j.ijid.2020.09.017. View

11.

Riou C, Gray C, Lugongolo M, Gwala T, Kiravu A, Deniso P . A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS One. 2014; 9(7):e102178. PMC: 4105550. DOI: 10.1371/journal.pone.0102178. View

12.

Goletti D, Arlehamn C, Scriba T, Anthony R, Cirillo D, Alonzi T . Can we predict tuberculosis cure? What tools are available?. Eur Respir J. 2018; 52(5). DOI: 10.1183/13993003.01089-2018. View

13.

Parrish N, Carroll K . Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. J Clin Microbiol. 2010; 49(3):772-6. PMC: 3067741. DOI: 10.1128/JCM.02451-10. View

14.

Lin P, Flynn J . CD8 T cells and Mycobacterium tuberculosis infection. Semin Immunopathol. 2015; 37(3):239-49. PMC: 4439333. DOI: 10.1007/s00281-015-0490-8. View

15.

Arrigucci R, Lakehal K, Vir P, Handler D, Davidow A, Herrera R . Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells. Front Immunol. 2018; 9:2127. PMC: 6156157. DOI: 10.3389/fimmu.2018.02127. View

16.

Gossez M, Rimmele T, Andrieu T, Debord S, Bayle F, Malcus C . Proof of concept study of mass cytometry in septic shock patients reveals novel immune alterations. Sci Rep. 2018; 8(1):17296. PMC: 6251894. DOI: 10.1038/s41598-018-35932-0. View

17.

Masungi C, Temmerman S, Van Vooren J, Drowart A, Pethe K, Menozzi F . Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis. 2002; 185(4):513-20. DOI: 10.1086/338833. View

18.

Ashhurst T, Marsh-Wakefield F, Putri G, Spiteri A, Shinko D, Read M . Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. Cytometry A. 2021; 101(3):237-253. DOI: 10.1002/cyto.a.24350. View

19.

Vickers M, Darboe F, Muefong C, Mbayo G, Barry A, Gindeh A . Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Specific T Cell Activation and Functional Markers. Front Immunol. 2021; 11:572620. PMC: 7931252. DOI: 10.3389/fimmu.2020.572620. View

20.

Ohnuma K, Dang N, Morimoto C . Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008; 29(6):295-301. DOI: 10.1016/j.it.2008.02.010. View